Journal article
New oral anticoagulants in elderly patients
Abstract
The new oral anticoagulants (NOACs) dabigatran etexilate, rivaroxaban, and apixaban have been extensively studied for prevention and treatment of venous thromboembolic disease and for stroke prevention in atrial fibrillation. Elderly patients have the highest incidence of thrombotic complications but also have the highest risk of anticoagulant associated bleeding. In this review we critically examine the balance between risks and benefits of …
Authors
Barco S; Cheung YW; Eikelboom JW; Coppens M
Journal
Best Practice & Research Clinical Haematology, Vol. 26, No. 2, pp. 215–224
Publisher
Elsevier
Publication Date
June 2013
DOI
10.1016/j.beha.2013.07.011
ISSN
1521-6926